Literature DB >> 12654847

Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.

Jim Hill1, Catherine Copse, Sophie Leary, Anthony J Stagg, E Diane Williamson, Richard W Titball.   

Abstract

Monoclonal antibodies specific for Yersinia pestis V antigen and F1 antigen, administered singly or in combination, protected mice in models of bubonic and pneumonic plague. Antibodies showed synergy when administered prophylactically and as a therapy 48 h postinfection. Monoclonal antibodies therefore have potential as a treatment for plague.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12654847      PMCID： PMC152045          DOI： 10.1128/IAI.71.4.2234-2238.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  43 in total

Review 1.  Plague vaccine research and development.

Authors:  E D Williamson
Journal:  J Appl Microbiol       Date:  2001-10       Impact factor: 3.772

2.  A single dose sub-unit vaccine protects against pneumonic plague.

Authors:  E D Williamson; S M Eley; A J Stagg; M Green; P Russell; R W Titball
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

Review 3.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

4.  Identification of Yersinia pestis as the causative organism of plague in India as determined by 16S rDNA sequencing and RAPD-based genomic fingerprinting.

Authors:  S Shivaji; N V Bhanu; R K Aggarwal
Journal:  FEMS Microbiol Lett       Date:  2000-08-15       Impact factor: 2.742

5.  Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.

Authors:  A Knappik; L Ge; A Honegger; P Pack; M Fischer; G Wellnhofer; A Hoess; J Wölle; A Plückthun; B Virnekäs
Journal:  J Mol Biol       Date:  2000-02-11       Impact factor: 5.469

6.  [Resurgence of the plague in the Ikongo district of Madagascar in 1998. 1. Epidemiological aspects in the human population].

Authors:  R Migliani; M Ratsitorahina; L Rahalison; I Rakotoarivony; J B Duchemin; J M Duplantier; J Rakotonomenjanahary; S Chanteau
Journal:  Bull Soc Pathol Exot       Date:  2001-05

7.  [Resurgence of the plague in the Ikongo district of Madagascar in 1998. 2. Reservoirs and vectors implicated].

Authors:  J M Duplantier; J B Duchemin; M Ratsitorahina; L Rahalison; S Chanteau
Journal:  Bull Soc Pathol Exot       Date:  2001-05

8.  Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.

Authors:  N Shime; T Sawa; J Fujimoto; K Faure; L R Allmond; T Karaca; B L Swanson; E G Spack; J P Wiener-Kronish
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

9.  Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization.

Authors:  J Hill; S E Leary; K F Griffin; E D Williamson; R W Titball
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

10.  Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis.

Authors:  A Guiyoule; G Gerbaud; C Buchrieser; M Galimand; L Rahalison; S Chanteau; P Courvalin; E Carniel
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883
View more
  41 in total

1.  Administration of antibody to the lung protects mice against pneumonic plague.

Authors:  Jim Hill; Jim E Eyles; Stephen J Elvin; Gareth D Healey; Roman A Lukaszewski; Richard W Titball
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis.

Authors:  Ho-Ki Shim; Julie A Musson; Helen M Harper; Hesta V McNeill; Nicola Walker; Helen Flick-Smith; Alexei von Delwig; E Diane Williamson; John H Robinson
Journal:  Immunology       Date:  2006-08-18       Impact factor: 7.397

3.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

4.  Antibody Opsonization Enhances Early Interactions between Yersinia pestis and Neutrophils in the Skin and Draining Lymph Node in a Mouse Model of Bubonic Plague.

Authors:  Jeffrey G Shannon; B Joseph Hinnebusch
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

5.  Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion.

Authors:  Addie Embry; Xiangzhi Meng; Angelene Cantwell; Peter H Dube; Yan Xiang
Journal:  Vaccine       Date:  2011-06-12       Impact factor: 3.641

6.  Amino acid residues 196-225 of LcrV represent a plague protective epitope.

Authors:  Lauriane E Quenee; Bryan J Berube; Joshua Segal; Derek Elli; Nancy A Ciletti; Deborah Anderson; Olaf Schneewind
Journal:  Vaccine       Date:  2009-12-10       Impact factor: 3.641

7.  Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.

Authors:  Xiaodong Xiao; Zhongyu Zhu; Jennifer L Dankmeyer; Michael M Wormald; Randy L Fast; Patricia L Worsham; Christopher K Cote; Kei Amemiya; Dimiter S Dimitrov
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

Review 8.  Protecting against plague: towards a next-generation vaccine.

Authors:  E D Williamson; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

9.  The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes.

Authors:  Julien Goure; Alexandrine Pastor; Eric Faudry; Jacqueline Chabert; Andréa Dessen; Ina Attree
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.

Authors:  Betty L Noel; Sarit Lilo; Daniel Capurso; Jim Hill; James B Bliska
Journal:  Clin Vaccine Immunol       Date:  2009-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.